All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On July 6, 2020, the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on the phase II clinical trial of camidanlumab tesirine in patients with relapsed or refractory (R/R) Hodgkin lymphoma (HL).
Camidanlumab tesirine is an anti-CD25 antibody-drug conjugate which is being evaluated for patients with R/R classical HL (cHL). At the 15th International Conference on Malignant Lymphoma (ICML), the lymphoma hub spoke to Graham Collins, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, who reported the results of the phase I trial (watch the video here).
The pivotal phase II (NCT04052997) multi-center, open-label, single-arm clinical trial is evaluating the safety and efficacy of camidanlumab tesirine in patients with R/R cHL. Patients with R/R cHL who failed three previous lines of therapy including brentuximab vedotin and a checkpoint inhibitor approved for cHL (e.g. nivolumab or pembrolizumab) were eligible for the study. Patients already enrolled in the trial continued to be treated during the partial clinical hold, and now that the hold has been lifted, additional patient enrolment can resume.
The study is expected to support the submission of a Biologics License Application to the FDA.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox